Citation
Derosa, G, et al. "Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 42, no. 9, 2010, pp. 663-9.
Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42(9):663-9.
Derosa, G., Maffioli, P., Ferrari, I., Mereu, R., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., D'Angelo, A., & Salvadeo, S. A. (2010). Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 42(9), 663-9. https://doi.org/10.1055/s-0030-1255036
Derosa G, et al. Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients. Horm Metab Res. 2010;42(9):663-9. PubMed PMID: 20560108.
TY - JOUR
T1 - Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
AU - Derosa,G,
AU - Maffioli,P,
AU - Ferrari,I,
AU - Mereu,R,
AU - Ragonesi,P D,
AU - Querci,F,
AU - Franzetti,I G,
AU - Gadaleta,G,
AU - Ciccarelli,L,
AU - Piccinni,M N,
AU - D'Angelo,A,
AU - Salvadeo,S A T,
Y1 - 2010/06/17/
PY - 2010/6/19/entrez
PY - 2010/6/19/pubmed
PY - 2010/12/14/medline
SP - 663
EP - 9
JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
JO - Horm Metab Res
VL - 42
IS - 9
N2 - The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM). 168 patients with T2DM were randomized to take either pioglitazone 30 mg once a day plus vildagliptin 50 mg twice a day or glimepiride 2 mg 3 times a day plus vildagliptin 50 mg twice a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment beta-cell function index (HOMA-beta), fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), adiponectin (ADN), resistin (R), tumor necrosis factor-alpha (TNF-alpha), and high sensitivity C-reactive protein (Hs-CRP) at their baseline values, and after 3, 6, 9, and 12 months of treatment. We observed a similar improvement of HbA1c, FPG, PPG, and Hs-CRP compared to baseline in the 2 groups. Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF-alpha were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin. HOMA-IR, and HOMA-beta values obtained with pioglitazone plus vildagliptin were significantly better than the values obtained with glimepiride plus vildagliptin. Pioglitazone plus vildagliptin were found to be more effective in preserving beta-cell function, and in reducing insulin resistance, and inflammatory state parameters.
SN - 1439-4286
UR - https://www.unboundmedicine.com/medline/citation/20560108/Effects_of_one_year_treatment_of_vildagliptin_added_to_pioglitazone_or_glimepiride_in_poorly_controlled_type_2_diabetic_patients_
L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1255036
DB - PRIME
DP - Unbound Medicine
ER -
